Literature DB >> 20194704

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

K Kosowska-Shick1, P L McGhee, P C Appelbaum.   

Abstract

We compared the affinities of ceftaroline for all penicillin-binding proteins (PBPs) with those of ceftriaxone and cefotaxime in 6 Staphylococcus aureus and 7 Streptococcus pneumoniae isolates with various resistance phenotypes. Ceftaroline MICs were <or=1 microg/ml against all S. aureus isolates and were <or=0.25 microg/ml for 4 of 7 isolates of S. pneumoniae. Ceftaroline affinities for penicillin-susceptible S. pneumoniae strains were in the order PBP2X and -3 > PBP1A, -1B, and -2A > PBP2B, and ceftaroline had >or=4-fold higher 50% inhibitory concentrations (IC(50)s) (0.1 to 4 microg/ml) for PBP2X, -2A, -2B, and -3 than those for the other cephalosporins tested. Among 3 penicillin-resistant S. pneumoniae strains, ceftaroline had a high affinity for PBP2X (IC(50), 0.1 to 1 microg/ml), a primary target for cephalosporin PBP binding activity, and high affinities for PBP2B (IC(50), 0.5 to 4 microg/ml) and PBP1A (IC(50), 0.125 to 0.25 microg/ml) as well, both of which are also known as major targets for PBP binding activity of cephalosporins. Ceftaroline PBP affinities in methicillin-susceptible S. aureus strains were greater than or equal to those of the 3 other beta-lactams tested. Ceftaroline bound to PBP2a in methicillin-resistant S. aureus (IC(50), 0.01 to 1 microg/ml) with up to 256-fold-higher affinity than those of other agents. Ceftaroline demonstrated very good PBP affinity against all S. aureus and S. pneumoniae strains tested, including resistant isolates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194704      PMCID: PMC2863635          DOI: 10.1128/AAC.00019-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  61 in total

1.  Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae.

Authors:  R Muñoz; C G Dowson; M Daniels; T J Coffey; C Martin; R Hakenbeck; B G Spratt
Journal:  Mol Microbiol       Date:  1992-09       Impact factor: 3.501

2.  Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus.

Authors:  H F Chambers; M Sachdeva
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

3.  Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A.

Authors:  B L de Jonge; Y S Chang; D Gage; A Tomasz
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

4.  Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion.

Authors:  M D Song; M Wachi; M Doi; F Ishino; M Matsuhashi
Journal:  FEBS Lett       Date:  1987-08-31       Impact factor: 4.124

5.  Emergence of methicillin-resistant clones from cephamycin-resistant Staphylococcus aureus.

Authors:  K Okonogi; Y Noji; M Kondo; A Imada; T Yokota
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

6.  Interaction of non-lytic beta-lactams with penicillin-binding proteins in Streptococcus pneumoniae.

Authors:  R Hakenbeck; S Tornette; N F Adkinson
Journal:  J Gen Microbiol       Date:  1987-03

7.  Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  G Laible; B G Spratt; R Hakenbeck
Journal:  Mol Microbiol       Date:  1991-08       Impact factor: 3.501

8.  Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  Hélène Moisan; Mireille Pruneau; François Malouin
Journal:  J Antimicrob Chemother       Date:  2010-01-22       Impact factor: 5.790

9.  Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus.

Authors:  B L de Jonge; T Sidow; Y S Chang; H Labischinski; B Berger-Bachi; D A Gage; A Tomasz
Journal:  J Bacteriol       Date:  1993-05       Impact factor: 3.490

10.  Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus.

Authors:  Y Utsui; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

View more
  53 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

3.  Prolonged Exposure to β-Lactam Antibiotics Reestablishes Susceptibility of Daptomycin-Nonsusceptible Staphylococcus aureus to Daptomycin.

Authors:  Rachel E Jenson; Sarah L Baines; Benjamin P Howden; Nagendra N Mishra; Sabrina Farah; Cassandra Lew; Andrew D Berti; Sanjay K Shukla; Arnold S Bayer; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Authors:  Helio S Sader; Robert K Flamm; Jennifer M Streit; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient.

Authors:  Leah Molloy; Ashley Hall Snyder; Ruma Srivastava; Michael J Rybak; Eric McGrath
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

Review 6.  Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  H Andrew Wilsey; Donna R Burgess; David S Burgess
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

7.  Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.

Authors:  Astrid Zervosen; André Zapun; Jean-Marie Frère
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

8.  Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.

Authors:  Rebecca A Keel; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

9.  Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 10.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.